DexCom Inc (DXCM) director’s family trust sells 4,000 shares under 10b5-1 plan
Rhea-AI Filing Summary
A family trust associated with DexCom Inc. director Mark G. Foletta sold 4,000 shares of common stock in two indirect open-market transactions: 2,000 shares at $80.00 on July 31, 2026 and 2,000 shares at $85.32 on August 3, 2026, pursuant to a pre‑arranged 10b5‑1 Plan adopted by the Foletta Family Trust on March 13, 2026.
Foletta also directly holds 6,331 unvested restricted stock units granted on May 28, 2026, scheduled to vest on the earlier of the one‑year grant anniversary or DexCom’s 2027 annual meeting of stockholders.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 4,000 shares
Net Sell
3 txns
Insider
FOLETTA MARK G
Role
Director
Sold
4,000 shs ($331K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 2,000 | $85.32 | $171K |
| Sale | Common Stock F1, F2 | 2,000 | $80.00 | $160K |
| holding | Common Stock F3 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 48,852 shares (Indirect, by Trust);
Common Stock — 6,331 shares (Direct)
Footnotes (3)
- F1. On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- F2. Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
- F3. Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.
Key Figures
Shares sold on 2026-08-03: 2000.0000 shares
Sale price on 2026-08-03: $85.3200 per share
Shares sold on 2026-07-31: 2000.0000 shares
+2 more
5 metrics
Shares sold on 2026-08-03
2000.0000 shares
Common stock sold indirectly by The Foletta Family Trust on August 3, 2026
Sale price on 2026-08-03
$85.3200 per share
Per‑share price for 2,000 DexCom common shares sold on August 3, 2026
Shares sold on 2026-07-31
2000.0000 shares
Common stock sold indirectly by The Foletta Family Trust on July 31, 2026
Sale price on 2026-07-31
$80.0000 per share
Per‑share price for 2,000 DexCom common shares sold on July 31, 2026
Unvested restricted stock units
6331.0000 units
Unvested RSUs granted to Mark G. Foletta on May 28, 2026
Key Terms
10b5-1 Plan, restricted stock units, Trust
3 terms
10b5-1 Plan regulatory
"On March 13, 2026, The Foletta Family Trust ... adopted a 10b5-1 Plan."
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
restricted stock units financial
"Represents unvested restricted stock units which were granted on May 28, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Trust financial
"Shares are held by The Foletta Family Trust DTD 1/30/2015"
A trust is a legal setup in which one party (the trustee) holds and manages assets—like cash, stocks or property—on behalf of other people (beneficiaries) according to instructions from the person who created it (the grantor). Think of it as a locked box with a keyholder who must follow written rules; for investors it matters because trusts influence who controls and benefits from assets, affect taxes and succession, and can change how quickly or transparently shares are bought, sold or voted.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock sales in DexCom (DXCM) did Mark G. Foletta report?
A family trust for DexCom director Mark G. Foletta sold 4,000 shares of common stock in two indirect open‑market transactions, 2,000 shares on July 31, 2026 and 2,000 shares on August 3, 2026, at prices of $80.00 and $85.32 per share, respectively.
Were the recent DexCom (DXCM) insider sales made under a Rule 10b5-1 plan?
Yes. The Foletta Family Trust adopted a 10b5‑1 Plan on March 13, 2026. The 2,000‑share sale at $80.00 on July 31, 2026 and the 2,000‑share sale at $85.32 on August 3, 2026 were executed pursuant to that trading plan.
What DexCom (DXCM) equity awards does Mark G. Foletta hold after these transactions?
Mark G. Foletta directly holds 6,331 unvested restricted stock units. These RSUs were granted on May 28, 2026 and are scheduled to vest on the earlier of the one‑year anniversary of the grant date or DexCom’s 2027 annual meeting of stockholders.
Is Mark G. Foletta’s DexCom (DXCM) ownership reported as direct or through a trust?
The reported stock sales involve shares held by The Foletta Family Trust, for which he serves as trustee, reflecting indirect ownership. Separately, the filing shows he directly holds 6,331 unvested restricted stock units granted on May 28, 2026.